Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24954342,T1/2,"Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),h,1.9,2086,DB00461,Nabumetone
,24954342,"Css, muscle/Css","Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),,0.85,2087,DB00461,Nabumetone
,10841070,plasma half-life,The long plasma half-life of 6-MNA (20 to 24 hours) and its persistence in synovial fluid facilitate a once-daily dosage regimen.,[Properties and features of nabumetone]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841070/),h,20 to 24,9960,DB00461,Nabumetone
,1474531,time to maximum plasma concentration,"At steady state, the time to maximum plasma concentration for 6MNA is 1 to 4 h.",An overview of the clinical pharmacokinetics of nabumetone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474531/),h,1 to 4,15264,DB00461,Nabumetone
,1474531,half-life,6MNA has a very low clearance rate and long half-life (about 24 h).,An overview of the clinical pharmacokinetics of nabumetone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474531/),h,24,15265,DB00461,Nabumetone
,18651608,total chromatographic runtime,"The total chromatographic runtime was 3.0 min with retention time for 6-MNA and IS at 1.97 and 1.26 min, respectively.","High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651608/),min,3.0,18842,DB00461,Nabumetone
,18651608,retention time,"The total chromatographic runtime was 3.0 min with retention time for 6-MNA and IS at 1.97 and 1.26 min, respectively.","High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651608/),min,1.97,18843,DB00461,Nabumetone
,18651608,retention time,"The total chromatographic runtime was 3.0 min with retention time for 6-MNA and IS at 1.97 and 1.26 min, respectively.","High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651608/),min,1.26,18844,DB00461,Nabumetone
,21650014,recovery,"The recovery reached approximately 84% and 86-90% for nabumetone and 6-MNA, respectively.",[Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21650014/),%,84,36734,DB00461,Nabumetone
,21650014,recovery,"The recovery reached approximately 84% and 86-90% for nabumetone and 6-MNA, respectively.",[Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21650014/),%,86-90,36735,DB00461,Nabumetone
,21650014,limit of UV detection,"The limit of UV detection was 50 nM and 0.1 microM for 6-MNA and nabumetone, respectively.",[Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21650014/),nM,50,36736,DB00461,Nabumetone
,21650014,limit of UV detection,"The limit of UV detection was 50 nM and 0.1 microM for 6-MNA and nabumetone, respectively.",[Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21650014/),μM,0.1,36737,DB00461,Nabumetone
,21650014,limit of MS detection,"The limit of MS detection was 1 microM and 0.5 microM for 6-MNA and nabumetone, respectively.",[Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21650014/),μM,1,36738,DB00461,Nabumetone
,21650014,limit of MS detection,"The limit of MS detection was 1 microM and 0.5 microM for 6-MNA and nabumetone, respectively.",[Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21650014/),μM,0.5,36739,DB00461,Nabumetone
,21650014,Precision,"Precision ranged between 4.2-14.4% and 4.6-8.5% using UV and MS detection for nabumetone, respectively.",[Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21650014/),%,4.2-14.4,36740,DB00461,Nabumetone
,21650014,Precision,"Precision ranged between 4.2-14.4% and 4.6-8.5% using UV and MS detection for nabumetone, respectively.",[Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21650014/),%,4.6-8.5,36741,DB00461,Nabumetone
,6688407,maximum plasma concentrations,"After doses of 250, 500, and 1000 mg nabumetone, maximum plasma concentrations of the major metabolite, 6-methoxy-2-naphthylacetic acid, were 9.76, 24.19, and 36.59 micrograms/ml, in nonfasting subjects.","Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688407/),[μg] / [ml],9.76,54725,DB00461,Nabumetone
,6688407,maximum plasma concentrations,"After doses of 250, 500, and 1000 mg nabumetone, maximum plasma concentrations of the major metabolite, 6-methoxy-2-naphthylacetic acid, were 9.76, 24.19, and 36.59 micrograms/ml, in nonfasting subjects.","Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688407/),[μg] / [ml],24.19,54726,DB00461,Nabumetone
,6688407,maximum plasma concentrations,"After doses of 250, 500, and 1000 mg nabumetone, maximum plasma concentrations of the major metabolite, 6-methoxy-2-naphthylacetic acid, were 9.76, 24.19, and 36.59 micrograms/ml, in nonfasting subjects.","Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688407/),[μg] / [ml],36.59,54727,DB00461,Nabumetone
,27714886,Tmax,Tmax of 6-MNA has been increased to 2 h from 1.5 h in AN + NAB treated group.,Pharmacokinetic and Pharmacodynamic Interaction of Andrographolide and Standardized Extract of Andrographis paniculata (Nees) with Nabumetone in Wistar Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27714886/),h,2,61141,DB00461,Nabumetone
,27714886,Tmax,Tmax of 6-MNA has been increased to 2 h from 1.5 h in AN + NAB treated group.,Pharmacokinetic and Pharmacodynamic Interaction of Andrographolide and Standardized Extract of Andrographis paniculata (Nees) with Nabumetone in Wistar Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27714886/),h,1.5,61142,DB00461,Nabumetone
,3759278,Cmax,In the patients with liver insufficiency the mean values of Cmax and AUC0-24 h for 6-methoxy-2-naphthylacetic acid were 26.75 +/- 8.45 mg/l and 623.64 +/- 161.8 mg X h/l respectively.,Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3759278/),[mg] / [l],26.75,75312,DB00461,Nabumetone
,3759278,AUC0-24 h,In the patients with liver insufficiency the mean values of Cmax and AUC0-24 h for 6-methoxy-2-naphthylacetic acid were 26.75 +/- 8.45 mg/l and 623.64 +/- 161.8 mg X h/l respectively.,Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3759278/),[h·mg] / [l],623.64,75313,DB00461,Nabumetone
,3759278,Tmax,"The Tmax-value was prolonged to 8 h, compared to 4 h Tmax-value of the volunteers.",Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3759278/),h,8,75314,DB00461,Nabumetone
,3759278,Tmax,"The Tmax-value was prolonged to 8 h, compared to 4 h Tmax-value of the volunteers.",Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3759278/),h,4,75315,DB00461,Nabumetone
,32380748,residual drug,"Photostability increased significantly for both drugs in the liquid microemulsion and microemulsion-in-gel, compared to the ethanol solution and plain gel, reaching a residual drug of 97% and 98% for Nabumetone and analog in microemulsion-in-gel, respectively.",Gel Formulation of Nabumetone and a Newly Synthesized Analog: Microemulsion as a Photoprotective Topical Delivery System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32380748/),%,97,95291,DB00461,Nabumetone
,32380748,residual drug,"Photostability increased significantly for both drugs in the liquid microemulsion and microemulsion-in-gel, compared to the ethanol solution and plain gel, reaching a residual drug of 97% and 98% for Nabumetone and analog in microemulsion-in-gel, respectively.",Gel Formulation of Nabumetone and a Newly Synthesized Analog: Microemulsion as a Photoprotective Topical Delivery System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32380748/),%,98,95292,DB00461,Nabumetone
,25393072,Cmax,"In this open-label, laboratory-blinded, 2-way single dose study in 24 volunteers of both sexes we found that (1) nabumetone reaches mean Cmax ± SD of 0.56 ± 0.20 mg·","Nabumetone and 6-MNA Pharmacokinetics, Assessment of Intrasubject Variability and Gender Effect. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393072/),mg,0.56,98856,DB00461,Nabumetone
,25393072,tmax,"L at mean tmax of 8.63 ± 7.05 hours, and mean area under the curve (AUC)last of 18.07 ± 7.19 h·mg·L; (2) there are no statistically significant differences between both sexes in pharmacokinetics of nabumetone; (3) 6-methoxy-2-naphthylacetic acid (6-MNA) reaches higher AUClast in men compared with women (mean ± SD, 721.23 ± 185.53 h·mg·L and 545.27 ± 97.69 h·mg·L, respectively; P = 0.013); (4) there is lower 6-MNA clearance in men (0.65 ± 0.22 L·h) in comparison with women (0.88 ± 0.18 L·h, P = 0.019), (5) intersubject variability of nabumetone and 6-MNA is between 35%-45% and 10%-30% for all assessed pharmacokinetics parameters (AUClast, Cmax, partial AUC values); (6) intrasubject variability (ISCV) for AUClast is low, 15.59% and 6.40% for nabumetone and 6-MNA, respectively, (7) ISCV for Cmax is 13.66% and 5.42% for nabumetone and 6-MNA, respectively.","Nabumetone and 6-MNA Pharmacokinetics, Assessment of Intrasubject Variability and Gender Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393072/),h,8.63,98857,DB00461,Nabumetone
,25393072,area under the curve (AUC)last,"L at mean tmax of 8.63 ± 7.05 hours, and mean area under the curve (AUC)last of 18.07 ± 7.19 h·mg·L; (2) there are no statistically significant differences between both sexes in pharmacokinetics of nabumetone; (3) 6-methoxy-2-naphthylacetic acid (6-MNA) reaches higher AUClast in men compared with women (mean ± SD, 721.23 ± 185.53 h·mg·L and 545.27 ± 97.69 h·mg·L, respectively; P = 0.013); (4) there is lower 6-MNA clearance in men (0.65 ± 0.22 L·h) in comparison with women (0.88 ± 0.18 L·h, P = 0.019), (5) intersubject variability of nabumetone and 6-MNA is between 35%-45% and 10%-30% for all assessed pharmacokinetics parameters (AUClast, Cmax, partial AUC values); (6) intrasubject variability (ISCV) for AUClast is low, 15.59% and 6.40% for nabumetone and 6-MNA, respectively, (7) ISCV for Cmax is 13.66% and 5.42% for nabumetone and 6-MNA, respectively.","Nabumetone and 6-MNA Pharmacokinetics, Assessment of Intrasubject Variability and Gender Effect. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393072/),h·l·mg,18.07,98858,DB00461,Nabumetone
,25393072,AUClast,"L at mean tmax of 8.63 ± 7.05 hours, and mean area under the curve (AUC)last of 18.07 ± 7.19 h·mg·L; (2) there are no statistically significant differences between both sexes in pharmacokinetics of nabumetone; (3) 6-methoxy-2-naphthylacetic acid (6-MNA) reaches higher AUClast in men compared with women (mean ± SD, 721.23 ± 185.53 h·mg·L and 545.27 ± 97.69 h·mg·L, respectively; P = 0.013); (4) there is lower 6-MNA clearance in men (0.65 ± 0.22 L·h) in comparison with women (0.88 ± 0.18 L·h, P = 0.019), (5) intersubject variability of nabumetone and 6-MNA is between 35%-45% and 10%-30% for all assessed pharmacokinetics parameters (AUClast, Cmax, partial AUC values); (6) intrasubject variability (ISCV) for AUClast is low, 15.59% and 6.40% for nabumetone and 6-MNA, respectively, (7) ISCV for Cmax is 13.66% and 5.42% for nabumetone and 6-MNA, respectively.","Nabumetone and 6-MNA Pharmacokinetics, Assessment of Intrasubject Variability and Gender Effect. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393072/),h·l·mg,721.23,98859,DB00461,Nabumetone
,25393072,AUClast,"L at mean tmax of 8.63 ± 7.05 hours, and mean area under the curve (AUC)last of 18.07 ± 7.19 h·mg·L; (2) there are no statistically significant differences between both sexes in pharmacokinetics of nabumetone; (3) 6-methoxy-2-naphthylacetic acid (6-MNA) reaches higher AUClast in men compared with women (mean ± SD, 721.23 ± 185.53 h·mg·L and 545.27 ± 97.69 h·mg·L, respectively; P = 0.013); (4) there is lower 6-MNA clearance in men (0.65 ± 0.22 L·h) in comparison with women (0.88 ± 0.18 L·h, P = 0.019), (5) intersubject variability of nabumetone and 6-MNA is between 35%-45% and 10%-30% for all assessed pharmacokinetics parameters (AUClast, Cmax, partial AUC values); (6) intrasubject variability (ISCV) for AUClast is low, 15.59% and 6.40% for nabumetone and 6-MNA, respectively, (7) ISCV for Cmax is 13.66% and 5.42% for nabumetone and 6-MNA, respectively.","Nabumetone and 6-MNA Pharmacokinetics, Assessment of Intrasubject Variability and Gender Effect. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393072/),h·l·mg,545.27,98860,DB00461,Nabumetone
,25393072,AUClast,"L at mean tmax of 8.63 ± 7.05 hours, and mean area under the curve (AUC)last of 18.07 ± 7.19 h·mg·L; (2) there are no statistically significant differences between both sexes in pharmacokinetics of nabumetone; (3) 6-methoxy-2-naphthylacetic acid (6-MNA) reaches higher AUClast in men compared with women (mean ± SD, 721.23 ± 185.53 h·mg·L and 545.27 ± 97.69 h·mg·L, respectively; P = 0.013); (4) there is lower 6-MNA clearance in men (0.65 ± 0.22 L·h) in comparison with women (0.88 ± 0.18 L·h, P = 0.019), (5) intersubject variability of nabumetone and 6-MNA is between 35%-45% and 10%-30% for all assessed pharmacokinetics parameters (AUClast, Cmax, partial AUC values); (6) intrasubject variability (ISCV) for AUClast is low, 15.59% and 6.40% for nabumetone and 6-MNA, respectively, (7) ISCV for Cmax is 13.66% and 5.42% for nabumetone and 6-MNA, respectively.","Nabumetone and 6-MNA Pharmacokinetics, Assessment of Intrasubject Variability and Gender Effect. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393072/),h·l,0.88,98861,DB00461,Nabumetone
,25393072,clearance,"L at mean tmax of 8.63 ± 7.05 hours, and mean area under the curve (AUC)last of 18.07 ± 7.19 h·mg·L; (2) there are no statistically significant differences between both sexes in pharmacokinetics of nabumetone; (3) 6-methoxy-2-naphthylacetic acid (6-MNA) reaches higher AUClast in men compared with women (mean ± SD, 721.23 ± 185.53 h·mg·L and 545.27 ± 97.69 h·mg·L, respectively; P = 0.013); (4) there is lower 6-MNA clearance in men (0.65 ± 0.22 L·h) in comparison with women (0.88 ± 0.18 L·h, P = 0.019), (5) intersubject variability of nabumetone and 6-MNA is between 35%-45% and 10%-30% for all assessed pharmacokinetics parameters (AUClast, Cmax, partial AUC values); (6) intrasubject variability (ISCV) for AUClast is low, 15.59% and 6.40% for nabumetone and 6-MNA, respectively, (7) ISCV for Cmax is 13.66% and 5.42% for nabumetone and 6-MNA, respectively.","Nabumetone and 6-MNA Pharmacokinetics, Assessment of Intrasubject Variability and Gender Effect. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393072/),h·l,0.65,98862,DB00461,Nabumetone
,25393072,clearance,"L at mean tmax of 8.63 ± 7.05 hours, and mean area under the curve (AUC)last of 18.07 ± 7.19 h·mg·L; (2) there are no statistically significant differences between both sexes in pharmacokinetics of nabumetone; (3) 6-methoxy-2-naphthylacetic acid (6-MNA) reaches higher AUClast in men compared with women (mean ± SD, 721.23 ± 185.53 h·mg·L and 545.27 ± 97.69 h·mg·L, respectively; P = 0.013); (4) there is lower 6-MNA clearance in men (0.65 ± 0.22 L·h) in comparison with women (0.88 ± 0.18 L·h, P = 0.019), (5) intersubject variability of nabumetone and 6-MNA is between 35%-45% and 10%-30% for all assessed pharmacokinetics parameters (AUClast, Cmax, partial AUC values); (6) intrasubject variability (ISCV) for AUClast is low, 15.59% and 6.40% for nabumetone and 6-MNA, respectively, (7) ISCV for Cmax is 13.66% and 5.42% for nabumetone and 6-MNA, respectively.","Nabumetone and 6-MNA Pharmacokinetics, Assessment of Intrasubject Variability and Gender Effect. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393072/),h·l,0.88,98863,DB00461,Nabumetone
,3688000,terminal plasma half-life,"In humans, relative bioavailability is similar after administration of different dose levels, the mean terminal plasma half-life of BRL 10720 being about 24 hours, allowing for once-daily dosing.","Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688000/),h,24,105878,DB00461,Nabumetone
,6526543,half-lives of the terminal beta-phase,The half-lives of the terminal beta-phase with mean values of 22.77 h and 22.0 h are of the same order of magnitude as those found in single dose studies.,Nabumetone--a novel anti-inflammatory drug: bioavailability after different dosage regimens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6526543/),h,22.77,107808,DB00461,Nabumetone
,6526543,half-lives of the terminal beta-phase,The half-lives of the terminal beta-phase with mean values of 22.77 h and 22.0 h are of the same order of magnitude as those found in single dose studies.,Nabumetone--a novel anti-inflammatory drug: bioavailability after different dosage regimens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6526543/),h,22.0,107809,DB00461,Nabumetone
,8894512,"""","The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],19.8,111072,DB00461,Nabumetone
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],19.8,111073,DB00461,Nabumetone
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],9.6,111074,DB00461,Nabumetone
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],32.5,111075,DB00461,Nabumetone
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],133.6,111076,DB00461,Nabumetone
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],18.3,111077,DB00461,Nabumetone
not exceed,8894512,Overall recovery,Overall recovery of the investigated compounds in lymph did not exceed 5% of the doses given.,Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),%,5,111078,DB00461,Nabumetone
,3687999,area under the curve,"The values of the pharmacokinetic parameters computed for tablet and suspension are presented in that order: area under the curve = 1,269:1,338 mg.hour/ml; absorption half-life = 1.04:0.83 hour; elimination half-life = 27.16:25.15 hours; lag time = 0.19:0.07 hour; peak concentration = 27.56:31.91 micrograms/ml, and time to peak concentration = 4.99:4.17 hours.",Bioequivalence study of nabumetone: tablet versus suspension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3687999/),[h·mg] / [ml],"1,269",130626,DB00461,Nabumetone
,3687999,absorption half-life,"The values of the pharmacokinetic parameters computed for tablet and suspension are presented in that order: area under the curve = 1,269:1,338 mg.hour/ml; absorption half-life = 1.04:0.83 hour; elimination half-life = 27.16:25.15 hours; lag time = 0.19:0.07 hour; peak concentration = 27.56:31.91 micrograms/ml, and time to peak concentration = 4.99:4.17 hours.",Bioequivalence study of nabumetone: tablet versus suspension. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3687999/),h,1.04,130627,DB00461,Nabumetone
,3687999,elimination half-life,"The values of the pharmacokinetic parameters computed for tablet and suspension are presented in that order: area under the curve = 1,269:1,338 mg.hour/ml; absorption half-life = 1.04:0.83 hour; elimination half-life = 27.16:25.15 hours; lag time = 0.19:0.07 hour; peak concentration = 27.56:31.91 micrograms/ml, and time to peak concentration = 4.99:4.17 hours.",Bioequivalence study of nabumetone: tablet versus suspension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3687999/),h,27.16,130628,DB00461,Nabumetone
,3687999,lag time,"The values of the pharmacokinetic parameters computed for tablet and suspension are presented in that order: area under the curve = 1,269:1,338 mg.hour/ml; absorption half-life = 1.04:0.83 hour; elimination half-life = 27.16:25.15 hours; lag time = 0.19:0.07 hour; peak concentration = 27.56:31.91 micrograms/ml, and time to peak concentration = 4.99:4.17 hours.",Bioequivalence study of nabumetone: tablet versus suspension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3687999/),h,0.19,130629,DB00461,Nabumetone
,3687999,peak concentration,"The values of the pharmacokinetic parameters computed for tablet and suspension are presented in that order: area under the curve = 1,269:1,338 mg.hour/ml; absorption half-life = 1.04:0.83 hour; elimination half-life = 27.16:25.15 hours; lag time = 0.19:0.07 hour; peak concentration = 27.56:31.91 micrograms/ml, and time to peak concentration = 4.99:4.17 hours.",Bioequivalence study of nabumetone: tablet versus suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3687999/),[μg] / [ml],27.56,130630,DB00461,Nabumetone
,3687999,time to peak concentration,"The values of the pharmacokinetic parameters computed for tablet and suspension are presented in that order: area under the curve = 1,269:1,338 mg.hour/ml; absorption half-life = 1.04:0.83 hour; elimination half-life = 27.16:25.15 hours; lag time = 0.19:0.07 hour; peak concentration = 27.56:31.91 micrograms/ml, and time to peak concentration = 4.99:4.17 hours.",Bioequivalence study of nabumetone: tablet versus suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3687999/),h,4.99,130631,DB00461,Nabumetone
,7781261,elimination half-life,The elimination half-life increased with decreased renal function and ranged from 22 to 44 hours.,Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781261/),h,22 to 44,185090,DB00461,Nabumetone
,7781261,apparent clearance,The apparent clearance determined by NONMEM analysis increased from 0.68 L/hr after a single dose to 1.13 L/hr at steady state.,Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781261/),[l] / [h],0.68,185091,DB00461,Nabumetone
,7781261,apparent clearance,The apparent clearance determined by NONMEM analysis increased from 0.68 L/hr after a single dose to 1.13 L/hr at steady state.,Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781261/),[l] / [h],1.13,185092,DB00461,Nabumetone
,7781261,apparent volume of distribution,The apparent volume of distribution was directly proportional to the nonalbumin protein concentration and ranged from 23 to 60 L.,Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781261/),l,23 to 60,185093,DB00461,Nabumetone
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],6.71,203929,DB00461,Nabumetone
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],3.24,203930,DB00461,Nabumetone
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],8.74,203931,DB00461,Nabumetone
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],46.05,203932,DB00461,Nabumetone
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],6.32,203933,DB00461,Nabumetone
not exceed,9167225,overall recovery,The overall recovery of the investigated compounds in lymph did not exceed 5% of the doses given.,Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),%,5,203934,DB00461,Nabumetone
,8712517,appearance half-life,Absorption of nabumetone from the gastrointestinal tract and its metabolism to 6MNA had a median appearance half-life of 0.88 hour.,"Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712517/),h,0.88,248119,DB00461,Nabumetone
,8712517,elimination half-life,The elimination half-life was 11 hours.,"Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712517/),h,11,248120,DB00461,Nabumetone
,8712517,Area under the plasma concentration time curve,Area under the plasma concentration time curve for 6MNA after oral administration of nabumetone was 120.6 mg/h/L.,"Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712517/),[mg] / [h·l],120.6,248121,DB00461,Nabumetone
,8712517,area under the plasma concentration time curve,"The area under the plasma concentration time curve for IV administration of 6MNA was 117.0 mg/h/L, and the specific volume of distribution was 0.247 L/kg.","Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712517/),[mg] / [h·l],117.0,248122,DB00461,Nabumetone
,8712517,specific volume of distribution,"The area under the plasma concentration time curve for IV administration of 6MNA was 117.0 mg/h/L, and the specific volume of distribution was 0.247 L/kg.","Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712517/),[l] / [kg],0.247,248123,DB00461,Nabumetone
,8712517,distribution half-life,"The distribution half-life and the elimination half-life were 0.56 and 7.90 hours, respectively.","Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712517/),h,0.56,248124,DB00461,Nabumetone
,8712517,elimination half-life,"The distribution half-life and the elimination half-life were 0.56 and 7.90 hours, respectively.","Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712517/),h,7.90,248125,DB00461,Nabumetone
,8712517,Percentage of total dose recovered,"Percentage of total dose recovered in urine for the 36-hour collection period after the oral and IV administrations was 7.4 and 5.3%, respectively.","Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712517/),%,7.4,248126,DB00461,Nabumetone
,8712517,Percentage of total dose recovered,"Percentage of total dose recovered in urine for the 36-hour collection period after the oral and IV administrations was 7.4 and 5.3%, respectively.","Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712517/),%,5.3,248127,DB00461,Nabumetone
,10821411,signal-to-noise ratio,"The lower limit of quantification (LLOQ) was 70 ng/ml, at a signal-to-noise ratio of 8:1.","Extractionless determination of 6-methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10821411/),,8:1,253378,DB00461,Nabumetone
,3688002,maximal plasma concentration,"These data were fitted to a single compartment model and the derived data are as follows: mean maximal plasma concentration, maximal time concentration, area under the plasma-time curve, elimination rate constant, and elimination half-life in the young group after single dose were 22.9, 8.4, 838, 0.032, and 21.2, respectively, whereas on steady-state, values were 33.6, 4.1, 666, 0.031, and 22.1, respectively.",Nabumetone kinetics in the young and elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,22.9,254770,DB00461,Nabumetone
,3688002,maximal time concentration,"These data were fitted to a single compartment model and the derived data are as follows: mean maximal plasma concentration, maximal time concentration, area under the plasma-time curve, elimination rate constant, and elimination half-life in the young group after single dose were 22.9, 8.4, 838, 0.032, and 21.2, respectively, whereas on steady-state, values were 33.6, 4.1, 666, 0.031, and 22.1, respectively.",Nabumetone kinetics in the young and elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,8.4,254771,DB00461,Nabumetone
,3688002,area under the plasma-time curve,"These data were fitted to a single compartment model and the derived data are as follows: mean maximal plasma concentration, maximal time concentration, area under the plasma-time curve, elimination rate constant, and elimination half-life in the young group after single dose were 22.9, 8.4, 838, 0.032, and 21.2, respectively, whereas on steady-state, values were 33.6, 4.1, 666, 0.031, and 22.1, respectively.",Nabumetone kinetics in the young and elderly. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,8.4,254772,DB00461,Nabumetone
,3688002,area under the plasma-time curve,"These data were fitted to a single compartment model and the derived data are as follows: mean maximal plasma concentration, maximal time concentration, area under the plasma-time curve, elimination rate constant, and elimination half-life in the young group after single dose were 22.9, 8.4, 838, 0.032, and 21.2, respectively, whereas on steady-state, values were 33.6, 4.1, 666, 0.031, and 22.1, respectively.",Nabumetone kinetics in the young and elderly. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,838,254773,DB00461,Nabumetone
,3688002,area under the plasma-time curve,"These data were fitted to a single compartment model and the derived data are as follows: mean maximal plasma concentration, maximal time concentration, area under the plasma-time curve, elimination rate constant, and elimination half-life in the young group after single dose were 22.9, 8.4, 838, 0.032, and 21.2, respectively, whereas on steady-state, values were 33.6, 4.1, 666, 0.031, and 22.1, respectively.",Nabumetone kinetics in the young and elderly. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,0.032,254774,DB00461,Nabumetone
,3688002,area under the plasma-time curve,"These data were fitted to a single compartment model and the derived data are as follows: mean maximal plasma concentration, maximal time concentration, area under the plasma-time curve, elimination rate constant, and elimination half-life in the young group after single dose were 22.9, 8.4, 838, 0.032, and 21.2, respectively, whereas on steady-state, values were 33.6, 4.1, 666, 0.031, and 22.1, respectively.",Nabumetone kinetics in the young and elderly. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,33.6,254775,DB00461,Nabumetone
,3688002,elimination rate constant,"These data were fitted to a single compartment model and the derived data are as follows: mean maximal plasma concentration, maximal time concentration, area under the plasma-time curve, elimination rate constant, and elimination half-life in the young group after single dose were 22.9, 8.4, 838, 0.032, and 21.2, respectively, whereas on steady-state, values were 33.6, 4.1, 666, 0.031, and 22.1, respectively.",Nabumetone kinetics in the young and elderly. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,8.4,254776,DB00461,Nabumetone
,3688002,elimination rate constant,"These data were fitted to a single compartment model and the derived data are as follows: mean maximal plasma concentration, maximal time concentration, area under the plasma-time curve, elimination rate constant, and elimination half-life in the young group after single dose were 22.9, 8.4, 838, 0.032, and 21.2, respectively, whereas on steady-state, values were 33.6, 4.1, 666, 0.031, and 22.1, respectively.",Nabumetone kinetics in the young and elderly. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,838,254777,DB00461,Nabumetone
,3688002,elimination rate constant,"These data were fitted to a single compartment model and the derived data are as follows: mean maximal plasma concentration, maximal time concentration, area under the plasma-time curve, elimination rate constant, and elimination half-life in the young group after single dose were 22.9, 8.4, 838, 0.032, and 21.2, respectively, whereas on steady-state, values were 33.6, 4.1, 666, 0.031, and 22.1, respectively.",Nabumetone kinetics in the young and elderly. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,0.032,254778,DB00461,Nabumetone
,3688002,elimination rate constant,"These data were fitted to a single compartment model and the derived data are as follows: mean maximal plasma concentration, maximal time concentration, area under the plasma-time curve, elimination rate constant, and elimination half-life in the young group after single dose were 22.9, 8.4, 838, 0.032, and 21.2, respectively, whereas on steady-state, values were 33.6, 4.1, 666, 0.031, and 22.1, respectively.",Nabumetone kinetics in the young and elderly. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,33.6,254779,DB00461,Nabumetone
,3688002,elimination half-life,"These data were fitted to a single compartment model and the derived data are as follows: mean maximal plasma concentration, maximal time concentration, area under the plasma-time curve, elimination rate constant, and elimination half-life in the young group after single dose were 22.9, 8.4, 838, 0.032, and 21.2, respectively, whereas on steady-state, values were 33.6, 4.1, 666, 0.031, and 22.1, respectively.",Nabumetone kinetics in the young and elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,21.2,254780,DB00461,Nabumetone
,3688002,steady,"These data were fitted to a single compartment model and the derived data are as follows: mean maximal plasma concentration, maximal time concentration, area under the plasma-time curve, elimination rate constant, and elimination half-life in the young group after single dose were 22.9, 8.4, 838, 0.032, and 21.2, respectively, whereas on steady-state, values were 33.6, 4.1, 666, 0.031, and 22.1, respectively.",Nabumetone kinetics in the young and elderly. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,22.1,254781,DB00461,Nabumetone
,3688002,accumulation ratio,The accumulation ratio was 1.6 in the young and 1.8 in the elderly.,Nabumetone kinetics in the young and elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,1.6,254782,DB00461,Nabumetone
,3688002,accumulation ratio,The accumulation ratio was 1.6 in the young and 1.8 in the elderly.,Nabumetone kinetics in the young and elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3688002/),,1.8,254783,DB00461,Nabumetone
